{
    "clinical_study": {
        "@rank": "80576", 
        "arm_group": [
            {
                "arm_group_label": "Continuation Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to this group will continue their ACE-I through the day of surgery"
            }, 
            {
                "arm_group_label": "Cessation Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose >48 hours prior to surgery)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effects of Angiotension Converting Enzyme\n      Inhibitors (ACE-I) during surgery and in the immediate postoperative period for patients\n      undergoing elective total hip or knee arthroplasty."
        }, 
        "brief_title": "ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adverse Effects of Angiotensin-converting-enzyme Inhibitors", 
            "Hypotension"
        ], 
        "condition_browse": {
            "mesh_term": "Hypotension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients electing to undergo primary or revision total hip or knee arthroplasty\n\n          -  Currently taking an ACE-I\n\n        Exclusion Criteria:\n\n          -  Trauma patients\n\n          -  Immunosuppressed patients (HIV/AIDS, organ transplant recipients, chemotherapy\n             patients, chronic steroid use)\n\n          -  Patients with history of severe hypertension related illness such as hypertension\n             associated with stroke or myocardial infarction\n\n          -  Patients in who continuation of their ACE-I is expressly mandated by their\n             prescribing physician"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867047", 
            "org_study_id": "Pro00037620", 
            "secondary_id": "Pro00037620"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cessation Group", 
                "description": "Subjects stop ACE-I 48 hours prior to surgery", 
                "intervention_name": "Cessation group", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Continuation Group", 
                "description": "Subjects take ACE-I through day of surgery", 
                "intervention_name": "Continuation group", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Angiotensin-Converting Enzyme Inhibitors", 
                "Enzyme Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "contact": {
                "email": "jennifer.friend@duke.edu", 
                "last_name": "Jennifer K Friend"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University"
            }, 
            "investigator": {
                "last_name": "Michael Bolognesi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Angiotensin Converting Enzyme Inhibitors on Total Hip and Knee Arthroplasty Patients", 
        "overall_contact": {
            "email": "michael.bolognesi@duke.edu", 
            "last_name": "Michael Bolognesi, MD"
        }, 
        "overall_contact_backup": {
            "email": "jennifer.friend@duke.edu", 
            "last_name": "Jennifer K Friend"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Michael Bolognesi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The number of instances of both mild (Systolic Blood Pressure less than 85 mmHG) and severe (Systolic Blood Pressure less than 65 mmHG) hypotension will be recorded.", 
                "measure": "Change in blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to discharge from hospital (approximately 6-8 weeks)"
            }, 
            {
                "description": "The number of times a vasopressors is provided to subjects will be recorded.", 
                "measure": "Number of times vasopressors given to subject both intraoperatively and postoperatively", 
                "safety_issue": "No", 
                "time_frame": "Discharge from hospital (approximately 5 days)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867047"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The number of instances that a subjects needs to be transferred to a step down unit or ICU will be recorded.", 
                "measure": "Number of instances subjects transferred to Intensive Care Unit (ICU)", 
                "safety_issue": "Yes", 
                "time_frame": "Discharge from hospital (approximately 5 days)"
            }, 
            {
                "description": "The number of instances that a subjects receives allogeneic blood will be recorded.", 
                "measure": "Number of instances that subject receives allogeneic blood", 
                "safety_issue": "Yes", 
                "time_frame": "Discharge from hospital (approximately 5 days)"
            }, 
            {
                "description": "Number of occurrences of acute kidney injury will be recorded.", 
                "measure": "Occurrence of acute kidney injury", 
                "safety_issue": "Yes", 
                "time_frame": "Discharge from hospital (approximately 5 days)"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}